Medical Oncology

Johns Hopkins

Questions discussed in this category

How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?

1 Answer available

Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?

1 Answer available

How would you treat a patient with metastatic RCC who developed posterior reversible encephalopathy syndrome (PRES) on a TKI-containing regimen?

Would you consider re-challenging with a different TKI?

1 Answer available

Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?

1 Answer available

For metastatic prostate cancer, when would you add carboplatin to docetaxel or cabazitaxel?

1 Answer available

How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

1 Answer available

For metastatic clear cell RCC, would you consider cabozantinib + nivolumab after progression on first line ipilimumab + nivolumab?

Or what is your preferred regimen for stage IV ccRCC following progression on IO/IO?

4 Answers available

How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

2 Answers available

How would you proceed for a patient with metastatic gastric-type adenocarcinoma, with vaginal and inguinofemoral disease only, who experiences complete response to her vaginal tumor but residual inguinal disease?

History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...

2 Answers available

How do you treat patients with newly diagnosed metastatic MiT Family Translocation Renal Cell Carcinoma?

MiT subfamily translocations = TFE3, TFEB, TFC, or MiTF

2 Answers available

After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?

Does post docetaxel PSA influence your decision?

1 Answer available

Are there any clinical scenarios where you would recommend adjuvant docetaxel for localized prostate cancer?

1 Answer available

How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Ann. Oncol.,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

JAMA Oncol,

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

Urology, 2001-08

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

Cancer, 2010-11-15

Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.

Ann Oncol, 2010 Feb 12

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

N Engl J Med, 2021 Mar 4

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J. Clin. Oncol., 2019 Jul 22

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Clinical genitourinary cancer, 2018-06

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Cancer treatment and research communications, 2019

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Urology, 2013-06

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Prostate Cancer Prostatic Dis, 2020 Feb 28

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Cancer, 2019 Dec 1

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Invest New Drugs, 2017 Oct 25

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.

Prostate cancer and prostatic diseases, 2018-04

Platinum sensitivity in metastatic prostate cancer: does histology matter?

JCO Precis Oncol, 2020

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

Lancet Oncol, 2019 Sep 09

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Prostate, 2022 Jun 08

The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

N Engl J Med, 2022 Feb 17

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Related Topics in Medical Oncology